当前位置: X-MOL 学术Gastric Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Gastric Cancer ( IF 6.0 ) Pub Date : 2021-09-01 , DOI: 10.1007/s10120-021-01227-z
Charles S Fuchs 1 , Mustafa Özgüroğlu 2 , Yung-Jue Bang 3 , Maria Di Bartolomeo 4 , Mario Mandala 5 , Min-Hee Ryu 6 , Lorenzo Fornaro 7 , Tomasz Olesinski 8 , Christian Caglevic 9 , Hyun C Chung 10 , Kei Muro 11 , Eric Van Cutsem 12 , Anneli Elme 13 , Peter Thuss-Patience 14 , Ian Chau 15 , Atsushi Ohtsu 16 , Pooja Bhagia 17 , Anran Wang 18 , Chie-Schin Shih 17 , Kohei Shitara 16
Affiliation  

Background

In the phase 3 KEYNOTE-061 study (cutoff: 10/26/2017), pembrolizumab did not significantly prolong OS vs paclitaxel as second-line (2L) therapy in PD-L1 combined positive score (CPS) ≥ 1 gastric/GEJ cancer. We present results in CPS ≥ 1, ≥ 5, and ≥ 10 populations after two additional years of follow-up (cutoff: 10/07/2019).

Methods

Patients were randomly allocated 1:1 to pembrolizumab 200 mg Q3W for ≤ 35 cycles or standard-dose paclitaxel. Primary endpoints: OS and PFS (CPS ≥ 1 population). HRs were calculated using stratified Cox proportional hazards models.

Results

366/395 patients (92.7%) with CPS ≥ 1 died. Pembrolizumab demonstrated a trend toward improved OS vs paclitaxel in the CPS ≥ 1 population (HR, 0.81); 24-month OS rates: 19.9% vs 8.5%. Pembrolizumab incrementally increased the OS benefit with PD-L1 enrichment (CPS ≥ 5: HR, 0.72, 24-month rate, 24.2% vs 8.8%; CPS ≥ 10: 0.69, 24-month rate, 32.1% vs 10.9%). There was no difference in median PFS among treatment groups (CPS ≥ 1: HR, 1.25; CPS ≥ 5: 0.98; CPS ≥ 10: 0.79). ORR (pembrolizumab vs paclitaxel) was 16.3% vs 13.6% (CPS ≥ 1), 20.0% vs 14.3% (CPS ≥ 5), and 24.5% vs 9.1% (CPS ≥ 10); median DOR was 19.1 months vs 5.2, 32.7 vs 4.8, and NR vs 6.9, respectively. Fewer treatment-related AEs (TRAEs) occurred with pembrolizumab than paclitaxel (53% vs 84%).

Conclusion

In this long-term analysis, 2L pembrolizumab did not significantly improve OS but was associated with higher 24-month OS rates than paclitaxel. Pembrolizumab also increased OS benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer TRAEs than paclitaxel.

Trial registration

ClinicalTrials.gov, NCT02370498



中文翻译:

派姆单抗与紫杉醇治疗既往治疗过的 PD-L1 阳性晚期胃癌或胃食管结合部癌:随机 3 期 KEYNOTE-061 试验的 2 年更新

背景

在 3 期 KEYNOTE-061 研究(截止日期:2017 年 10 月 26 日)中,与紫杉醇相比,派姆单抗在 PD-L1 联合阳性评分(CPS)≥1 胃癌/GEJ 癌中作为二线(2L)治疗没有显着延长 OS . 在额外两年的随访(截止日期:2019 年 7 月 10 日)后,我们展示了 CPS ≥ 1、≥ 5 和 ≥ 10 人群的结果。

方法

患者按 1:1 随机分配至派姆单抗 200 mg Q3W ≤ 35 个周期或标准剂量紫杉醇。主要终点:OS 和 PFS(CPS ≥ 1 人群)。使用分层 Cox 比例风险模型计算 HR。

结果

366/395 名 CPS ≥ 1 的患者 (92.7%) 死亡。在 CPS ≥ 1 人群中,派姆单抗与紫杉醇相比显示出改善 OS 的趋势(HR,0.81);24 个月操作系统率:19.9% 对 8.5%。Pembrolizumab 通过 PD-L1 富集逐渐增加了 OS 获益(CPS ≥ 5:HR,0.72,24 个月率,24.2% 对 8.8%;CPS ≥ 10:0.69,24 个月率,32.1% 对 10.9%)。治疗组之间的中位 PFS 没有差异(CPS ≥ 1:HR,1.25;CPS ≥ 5:0.98;CPS ≥ 10:0.79)。ORR(派姆单抗 vs 紫杉醇)分别为 16.3% vs 13.6%(CPS ≥ 1)、20.0% vs 14.3%(CPS ≥ 5)和 24.5% vs 9.1%(CPS ≥ 10);中位 DOR 分别为 19.1 个月对 5.2、32.7 对 4.8 个月和 NR 对 6.9。与紫杉醇相比,派姆单抗发生的治疗相关 AE (TRAE) 更少(53% 对 84%)。

结论

在这项长期分析中,2L 派姆单抗并未显着改善 OS,但与紫杉醇相比,其 24 个月 OS 率更高。Pembrolizumab 还通过 PD-L1 富集增加了 PD-L1 阳性胃癌 / GEJ 癌患者的 OS 益处,并且导致 TRAE 少于紫杉醇。

试用注册

ClinicalTrials.gov,NCT02370498

更新日期:2021-09-01
down
wechat
bug